Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
SBS-1000 was shown to be safe and well tolerated in healthy volunteers…
Tag: sparian
SBS-1000 was shown to be safe and well tolerated in healthy volunteers…
